Blue Cross Blue Shield
Natera's Signatera Gains First Commercial Payor Coverage in California, Louisiana
Blue Shield of California and Blue Cross and Blue Shield of Louisiana are each covering Signatera for multiple cancer indications.
If the Center for Genomic Interpretation's in silico quality assessment catches on with payors, some labs are sure to push back or propose data sharing as an alternative.
Highmark Asks Labs for Additional Validation Data on Cancer NGS Tests; Will Other Insurers Follow?
Premium
The payor wants to see data beyond what is required through CLIA, and recommends labs use the Center for Genomic Interpretation to gauge how well tests detect and interpret variants.
Biocept Lung Cancer Liquid Biopsy Test Obtains Coverage From Blue Cross Affiliate Highmark
After a two-year evaluation in advanced non-small cell lung cancers with Allegheny Health Network, the payor will cover the test for its regional members.
Wide Variation in Genomic Testing Utilization Across US, Report Finds
The report also identified opportunities to improve adoption through dissemination of evidence supporting the clinical and economic utilization of testing.